Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
1.1 (1y: -59%)
Market Cap 46 M P/E(ttm)
Enterprise Value 30.12 M P/B 3.50
MELA- NAS (USA)
Mela Sciences, Inc.
Not Rated
Top Ranked Predictable Companies
$1.10
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt No Debt
MELA's Cash to Debt is ranked lower than
628930% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.63 vs. MELA: No Debt )
MELA' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt
Equity to Asset 0.806
MELA's Equity to Asset is ranked lower than
699300% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.56 vs. MELA: 0.806 )
MELA' s 10-Year Equity to Asset Range
Min: 0.81   Max: 1
Current: 0.81
0.81
1
Interest Coverage No Debt
MELA's Interest Coverage is ranked lower than
877192% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 73.90 vs. MELA: No Debt )
MELA' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) -8174.50
MELA's Operating margin (%) is ranked lower than
892856% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.00 vs. MELA: -8174.50 )
MELA' s 10-Year Operating margin (%) Range
Min: -8174.5   Max: -869
Current: -8174.5
-8174.5
-869
Net-margin (%) -8155.8
MELA's Net-margin (%) is ranked lower than
980391% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.20 vs. MELA: -8155.8 )
MELA' s 10-Year Net-margin (%) Range
Min: -8155.8   Max: -1085.7
Current: -8155.8
-8155.8
-1085.7
ROE (%) -162.2
MELA's ROE (%) is ranked lower than
990098% of the 101 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.30 vs. MELA: -162.2 )
MELA' s 10-Year ROE (%) Range
Min: -162.2   Max: -59.8
Current: -162.2
-162.2
-59.8
ROA (%) -131.3
MELA's ROA (%) is ranked lower than
980391% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.30 vs. MELA: -131.3 )
MELA' s 10-Year ROA (%) Range
Min: -131.3   Max: -59.8
Current: -131.3
-131.3
-59.8
ROC (Joel Greenblatt) (%) -369.40
MELA's ROC (Joel Greenblatt) (%) is ranked lower than
900900% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.40 vs. MELA: -369.40 )
MELA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -369.4   Max: -51.9
Current: -369.4
-369.4
-51.9
» MELA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q3 2011

MELA Guru Trades in Q3 2011

Steven Cohen 16,200 sh (New)
» More
Q4 2011

MELA Guru Trades in Q4 2011

George Soros 1,000,000 sh (New)
Steven Cohen Sold Out
» More
Q1 2012

MELA Guru Trades in Q1 2012

George Soros 200,000 sh (-80%)
» More
Q2 2012

MELA Guru Trades in Q2 2012

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MELA

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-06-30 Sold Out 0.01%$2.51 - $4.74 $ 1.11-68%0
George Soros 2012-03-31 Reduce -80%0.13%$3.21 - $4.82 $ 1.11-73%200000
George Soros 2011-12-31 New Buy0.16%$3.5 - $6.62 $ 1.11-78%1000000
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Mela Sciences, Inc.

The Barclays Triggers More Insider Buying
March 13, 2013
Chuck Royce,Jim Simons - The Barclays Triggers More Insider Buying
The Barclays Global Healthcare Conference seems to have triggered a trend within insider trading in the medicine and healthcare industries. Earlier we saw five insider buys the day before Allscripts-Misys was set to present at the Barclays. Now there are two directors from AngioDynamics (ANGO) who invested nearly a million dollars back into their company the very day they were set to present at the conference. Chairman of the Board Vincent Bucci and Director Dennis Meteny bought 89,600 shares of AngioDynamics on Tuesday, March 12. Chairman Bucci bought 85,000 shares at $10.77 per share for a total of $915,450. Director Meteny bought 4,600 shares at $10.82 each for a total amount of $49,772. Bucci and Meteny now hold 133,696 and 21,950 shares, respectively. Read more...

Ratios

vs
industry		 vs
history
P/B 3.50
MELA's P/B is ranked lower than
657894% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.50 vs. MELA: 3.50 )
MELA' s 10-Year P/B Range
Min: 0   Max: 4.1
Current: 3.5
0
4.1
P/S 89.30
MELA's P/S is ranked lower than
628930% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.30 vs. MELA: 89.30 )
MELA' s 10-Year P/S Range
Min: 0   Max: 320.7
Current: 89.3
0
320.7
EV-to-EBIT 12.7
MELA's EV-to-EBIT is ranked lower than
704225% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.73 vs. MELA: 12.7 )
MELA' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 12.7

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 10.1
MELA's Price/Net Cash is ranked lower than
1999998% of the 50 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. MELA: 10.1 )
MELA' s 10-Year Price/Net Cash Range
Min: 0   Max: 0
Current: 10.1
Price/Net Current Asset Value 111
MELA's Price/Net Current Asset Value is ranked lower than
684931% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.00 vs. MELA: 111 )
MELA' s 10-Year Price/Net Current Asset Value Range
Min: 0   Max: 0
Current: 111
Price/Tangible Book 3.5
MELA's Price/Tangible Book is ranked lower than
704225% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.60 vs. MELA: 3.5 )
MELA' s 10-Year Price/Tangible Book Range
Min: 0   Max: 0
Current: 3.5

Business Description

MELA Sciences, Inc. commenced operations in December 1989 as a New York corporation, re-incorporated as a Delaware corporation in September 1997, and changed its name from Electro-Optical Sciences, Inc. to MELA Sciences, Inc. April 30, 2010. The Company is a medical device company engaged in designing and development of a non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma. The Company's flagship product, MelaFind is a non-invasive and objective computer vision system intended to aid in the early detection of melanoma. EOS designed MelaFind(R) to assist in the evaluation of pigmented skin lesions, including atypical moles, which have one or more clinical or historical characteristics of melanoma, before a final decision to biopsy has been rendered. MelaFind(R) acquires and displays multi-spectral (from blue to near infrared) digital images of pigmented skin lesions and uses automatic image analysis and statistical pattern recognition to help identify lesions to be considered for biopsy to rule out melanoma. The company's product MelaFind, is regulated as a medical device and is subject to extensive regulation by the FDA and other regulatory authorities in the U.S.
Company Website
SEC Reports
Industry: Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO
Traded in other countries:E2O.Germany
» More Articles for MELA

Headlines

Articles On GuruFocus.com
The Barclays Triggers More Insider Buying Mar 13 2013 
ElectroOptical Sciences Inc Reports Operating Results (10-K) Mar 03 2011 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) Nov 05 2010 
ElectroOptical Sciences Inc (MELA) CFO Richard I Steinhart buys 1,000 Shares Aug 12 2010 
ElectroOptical Sciences Inc (MELA) CEO Joseph V Gulfo buys 5,000 Shares Aug 12 2010 
ElectroOptical Sciences Inc (MELA) CEO Joseph V Gulfo buys 5,000 Shares Aug 12 2010 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) Aug 06 2010 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) May 10 2010 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) Nov 09 2009 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) Jul 24 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial